Birch Grove Capital LP Biomarin Pharmaceutical Inc Transaction History

Birch Grove Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 17, 2022	SELL	$74.28 - $92.69 $2.29 Million - $2.86 Million	-30,850 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $336,465 - $384,615	-4,500 Reduced 12.73%	30,850 $2.38 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $149,460 - $181,380	2,000 Added 6.0%	35,350 $2.67 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $486,487 - $604,340	6,700 Added 25.14%	33,350 $2.92 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $1.92 Million - $3.49 Million	26,650 New	26,650 $2.03 Million

623

181M

1.73M

1.73M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Birch Grove Capital LP, based on Form 13F filings with the SEC.

Stay updated on Birch Grove Capital LP with notifications on news.